TC3R News
Melanoma antigens in pediatric medulloblastoma contribute to tumor heterogeneity and species-specificity of group 3 tumors
The Fon Tacer lab found that over half of the most aggressive pediatric brain tumors activate MAGE genes—opening the door to new cancer immunotherapy strategies. The Fon Tacer lab recently published findings on melanoma-associated antigens (MAGEs) in pediatric medulloblastoma, which is the deadliest type of childhood brain cancer. These tumors are highly diverse, making them very difficult to treat. Identifying selective targets, biomarkers of responsiveness, and strategies to overcome resistance is critical. They found that more than half of group 3 medulloblastomas—the most aggressive subtype—activate MAGE genes, offering potential for patient stratification and new therapeutic approaches. MAGEs are tumor antigens and promising targets for cancer immunotherapy. This work is the result of several years of collaboration with researchers from UTSW and St. Jude Children’s Research Hospital (SJCRH).
School of Veterinary Medicine
-
Address
7671 Evans Drive, Amarillo, Texas 79106 -
Phone
806.742.3200 -
Email
SVM@ttu.edu